ATE478076T1 - Azaxanthonen zur behandlung von tumoren - Google Patents
Azaxanthonen zur behandlung von tumorenInfo
- Publication number
- ATE478076T1 ATE478076T1 AT06851384T AT06851384T ATE478076T1 AT E478076 T1 ATE478076 T1 AT E478076T1 AT 06851384 T AT06851384 T AT 06851384T AT 06851384 T AT06851384 T AT 06851384T AT E478076 T1 ATE478076 T1 AT E478076T1
- Authority
- AT
- Austria
- Prior art keywords
- tumors
- azaxanthones
- treatment
- mesenchymel
- retarding
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/301,930 US7772255B2 (en) | 2005-12-13 | 2005-12-13 | Method of treating tumors with azaxanthones |
| PCT/IB2006/004291 WO2008020269A2 (en) | 2005-12-13 | 2006-12-12 | A method of treating tumors with azaxanthones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478076T1 true ATE478076T1 (de) | 2010-09-15 |
Family
ID=38140264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06851384T ATE478076T1 (de) | 2005-12-13 | 2006-12-12 | Azaxanthonen zur behandlung von tumoren |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7772255B2 (de) |
| EP (1) | EP1968981B1 (de) |
| JP (1) | JP2009519318A (de) |
| AT (1) | ATE478076T1 (de) |
| CA (1) | CA2633112A1 (de) |
| DE (1) | DE602006016333D1 (de) |
| WO (1) | WO2008020269A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010089707A1 (en) * | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
| CN101899051B (zh) * | 2010-05-17 | 2013-03-20 | 中国人民解放军第二军医大学 | 1-氮杂呫吨酮-3-甲酰胺类化合物及制备方法和抗肿瘤用途 |
| WO2012016930A1 (en) | 2010-08-05 | 2012-02-09 | Universite De Droit Et Sante De Lille | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| WO2012112558A1 (en) | 2011-02-14 | 2012-08-23 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| US9365581B2 (en) | 2013-05-02 | 2016-06-14 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| US10966976B2 (en) | 2015-12-23 | 2021-04-06 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
| WO2017132538A1 (en) | 2016-01-29 | 2017-08-03 | The Regents Of The University Of Michigan | Amlexanox analogs |
| JP2020525434A (ja) * | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| CN109718374B (zh) * | 2017-10-27 | 2022-03-08 | 中国科学院分子细胞科学卓越创新中心 | Irf3抑制剂在制备yap过度激活的癌症的治疗或预防药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4143042A (en) | 1977-03-08 | 1979-03-06 | Takeda Chemical Industries, Ltd. | 1-azaxanthone-3-carboxylic acids |
| JPS53111096A (en) * | 1977-03-08 | 1978-09-28 | Takeda Chem Ind Ltd | 1-azaxanthone-3-carboxylic acid derivative and its preparation |
| US4539326A (en) * | 1982-08-20 | 1985-09-03 | Takeda Chemical Industries, Ltd. | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents |
| JP2963496B2 (ja) * | 1989-06-26 | 1999-10-18 | 第一製薬株式会社 | ベンゾピラノピリジン誘導体 |
| US6552055B2 (en) * | 1996-12-11 | 2003-04-22 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| EP1302470A4 (de) * | 2000-07-13 | 2005-04-06 | Takeda Pharmaceutical | Lipidreiche plaque-inhibitoren |
| US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
| DE10250081A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Vetmedica Gmbh | Wasserlösliche Meloxicam Granulate |
| WO2004054504A2 (en) * | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
-
2005
- 2005-12-13 US US11/301,930 patent/US7772255B2/en not_active Expired - Fee Related
-
2006
- 2006-12-12 CA CA002633112A patent/CA2633112A1/en not_active Abandoned
- 2006-12-12 DE DE602006016333T patent/DE602006016333D1/de active Active
- 2006-12-12 EP EP06851384A patent/EP1968981B1/de not_active Not-in-force
- 2006-12-12 AT AT06851384T patent/ATE478076T1/de not_active IP Right Cessation
- 2006-12-12 JP JP2008545146A patent/JP2009519318A/ja active Pending
- 2006-12-12 WO PCT/IB2006/004291 patent/WO2008020269A2/en not_active Ceased
-
2008
- 2008-10-21 US US12/255,141 patent/US20090042923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009519318A (ja) | 2009-05-14 |
| WO2008020269A2 (en) | 2008-02-21 |
| US7772255B2 (en) | 2010-08-10 |
| US20090042923A1 (en) | 2009-02-12 |
| HK1116186A1 (en) | 2008-12-19 |
| EP1968981A4 (de) | 2009-04-15 |
| CA2633112A1 (en) | 2008-02-21 |
| DE602006016333D1 (de) | 2010-09-30 |
| US20070135473A1 (en) | 2007-06-14 |
| EP1968981A2 (de) | 2008-09-17 |
| EP1968981B1 (de) | 2010-08-18 |
| WO2008020269A3 (en) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006014843D1 (de) | Verwendung von hif 1alfa modulatoren zur behandlung von krebs | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EP1844077A4 (de) | Dr5-antikörper und deren verwendung | |
| CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
| ATE295735T1 (de) | Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs | |
| GEAP202215447A (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| EA200701448A1 (ru) | Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного | |
| CY1117423T1 (el) | Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
| ATE448232T1 (de) | Substituierte heterozyklen | |
| EP4065691A4 (de) | Natürliche killerzellen-immuntherapie zur behandlung von glioblastom und anderen krebsformen | |
| NO20064794L (no) | Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon | |
| DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| ATE478076T1 (de) | Azaxanthonen zur behandlung von tumoren | |
| EP1694364A4 (de) | System zur behandlung und prävention von brustkrebs | |
| DE602005007220D1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |